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TGF-b1 Alters APC Preference, Polarizing
Islet Antigen Responses toward a Th2 Phenotype
from TGF-b1-deficient mice, which develop a multiple-
organ inflammatory disease that is lethal by 3±5 weeks
of age (Shull et al., 1992). Additionally, TGF-b1 inhibits
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Department of Immunology the production of proinflammatory cytokines from mac-
rophages, B cells, and T cells. TGF-b1 also affects anti-Scripps Research Institute
La Jolla, California 92037 gen presentation, e.g., by down-regulating the expres-
sion of major histocompatibility complex (MHC) class II
on both macrophages and B cells (Czarniecki et al.,
1988). Moreover, TGF-b1 blocks B cell proliferation, in-
Summary
hibits immunoglobulin G (IgG) and IgM mRNA synthesis,
and decreases membrane expression of immunoglobu-
TGF-b1, expressed in the pancreatic islets, protects
lin, compromising B cell responsiveness to antigen and
the nonobese diabetic (NOD) mouse from insulin- antigen presentation (Kehrl et al., 1991; Morikawa et al.,
dependent diabetes mellitus (IDDM). The islet antigen- 1993).
specific T cell response of ins-TGF-b1 mice relied on TGF-b1 appears to act differentially on T cells de-
different antigen-presenting cells (APC) from those pending upon their differentiation state and has been
used by NOD T cells. T cells from NOD mice utilized
reported tohave both inhibitory (Kehrl et al., 1986; Bright
B cells to present islet antigen, whereas T cells from
et al., 1997) and growth-promoting effects (Moses et al.,
ins-TGF-b1 mice utilized macrophages. In addition,
1992). TGF-b1, alone and in synergy with interleukin-2
the islet antigen-specific T cell repertoire of ins-TGF-
(IL-2), was shown to block apoptosis and promote the
b1 mice was distinct and deviated toward an IL-4-
expansion of antigen-specific, Th2-polarized effectors
producing Th2 phenotype. When ins-TGF-b1 mice were
generated in vitro from naive CD41 T cells of transgenic
treated with anti-IL-4 antibody, islet antigen-specific
mice (Zhang et al., 1995).
IFNg-producing Th1 cells were unleashed, and the in-
Considering these overall effects, TGF-b1 may also
cidence of diabetes increased to the level of NOD
prevent autoaggressive Th1-type responses. In models
mice. This suggests active suppression of a diabeto-
of oral tolerance, TGF-b1-producing cells appear capa-
genic T cell response. This study describes a novel ble of active immune suppression (Strober et al., 1997;
mechanism in which expression of TGF-b1 in the con- Weiner, 1997), and TGF-b1 appears to have a reciprocal
text of self-antigen shifts APC preference, deviating T relationship with interferon-g (IFNg) in regulating muco-
cell responses to a Th2 phenotype, preventing IDDM.
sal inflammation and autoreactive T cells in situ (Strober
et al., 1997). More recently, in vivo administration of
TGF-b1-blocking antibody has highlighted the role of
Introduction TGF-b1 in autoimmune regulation (Powrie et al., 1996;
Bridoux et al., 1997). Taken together, these data indicate
Autoreactive T cells that escape negative selection in that TGF-b1 is a key regulator of autoaggressive T cells
the thymus can be found in normal individuals, sug- in both diseased and nondiseased states. However, the
gesting that peripheral tolerance stems not from an ab- way in which TGF-b1 fits into the cross-regulatory rela-
sence of T cell reactivity to self-antigens per se but tionship between IL-4 and IFNg remains unclear.
rather from down-regulation of autoaggressive responses. The expression of TGF-b1 in the context of islet anti-
Extrathymic regulation of the development of autode- gen was found to protect susceptible mice from diabe-
structive T cells is maintained via a number of possible tes. This report describes studies performed to explore
mechanisms. They include clonal deletion (Webb et al., the mechanisms underlying this immunoprotection.Pro-
1990), anergy via functional inactivation (Mueller and tection from insulin-dependent diabetes mellitus (IDDM)
Jenkins, 1997), and suppression by regulatory thymo- in nonobese diabetic (NOD) mice that express TGF-b1
cytes (Fowell et al., 1995). Studies from our laboratory in their pancreatic islets of Langerhans was associated
(Sarvetnick et al., 1990; Mueller et al., 1996) and others with a distinct repertoire of peripherally expanded or
(Powrie et al., 1996) suggest that the cytokine mileu in influenced glutamicacid decarboxylase (GAD65) protein±
which self-antigen is expressed impacts greatly upon reactive T cells and the deviation of the response toward
peripheral tolerance. a Th2, or IL-4-producing, phenotype.
Transforming growth factor b (TGF-b1) belongs to a
family of polypeptide factors that regulate cell growth
Resultsand differentiation. TGF-b1 belongs to the T helper type
3 (Th3) group of cytokines and is known to inhibit cell
Expression of TGF-b1 in the Isletsgrowth and inflammation (Gray et al., 1994; Sitnicka et
of Langerhans in NOD Miceal., 1996; Strober et al., 1997). Convincing evidence for
The gene encoding porcine TGF-b1 was selectively di-the antiinflammatory role of TGF-b1 has been obtained
rected to the islets of Langerhans of the pancreas of
NOD mice via the human insulin promoter. The DNA
plasmid contained mutated porcine TGF-b1 with serine*To whom correspondence should be addressed (e-mail: noras@
scripps.edu). residues at amino acid positions 223 and 225, which
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Figure 1. Histological Analyses of Pancreata
of ins-TGF-b1 Mice and Their NOD Litter-
mates Stained for Expression of TGF-b1
Representative sections of the pancreas (n 5
10) reveal strong staining for TGF-b1 in the
pancreatic islets of a 12-week-old transgenic
female (A) but not in the islets of a NOD female
littermate (B). Histological analyses of pan-
creata of ins-TGF-b1 mice and their NOD lit-
termates stained for insulin positive islets.
Representative sections of the pancreas (n 5
8) reveal characteristic insulitis in the pan-
creas of a diabetic NOD female at 5 months
of age (C) but only periinsulitis in an 8-month-
old ins-TGF-b1 female (D). Splenocytes from
NOD mice transferred diabetes into NOD±
scid recipients, as evidenced by destruction
of insulin-staining islets (E). In contrast,
splenocytes from ins-TGF-b1 donors did not
cause disease and caused only periinsulitis
when transferred into NOD±scid recipients
(F). Transgenic expression of TGF-b1 does
not protect islets from destruction by spleno-
cytes from overtly diabetic NOD donors (G),
and NOD control recipients (H) show pan-
creata 5 days after transfer, stained for insu-
lin. Newborn pancreatic isografts from NOD
mice were tolerated by 8-month-old ins-TGF-
b1 mice, as demonstrated by insulin staining
islets (I). In contrast, newborn pancreatic iso-
grafts from ins-TGF-b1 mice were not toler-
ated in diabetic NOD recipients, as shown by
destruction of insulin-staining islets (J). Mag-
nification, 2003.
enables secretion of active molecules withoutacid treat- Expression of TGF-b1 in the Islets of Langerhans
Prevents Diabetes in NOD Micement. This sequence was inserted into a plasmid con-
taining the human insulin promotor and the terminator NOD mice bearing a transgene that produced TGF-b1
in their islets (ins-TGF-b1 mice) and their nontransgenicsequence from the hepatitis B virus gene. The fragment
encoding porcine TGF-b1 was microinjected into fertil- littermates were tested for the development of diabetes
by measuring their nonfasting blood glucose levelsized zygotes from NOD mice. Expression of TGF-b1 in
the islets was confirmed by staining of paraffin-embed- (BGL) (Figure 2). Nontransgenic mice spontaneously de-
veloped diabetes starting at 16 weeks of age, progress-ded sections of pancreata from ins-TGF-b1 mice and
their nontransgenic littermates as controls, using poly- ing until 75% of females and 25% of males were affected
by 32 weeks of age, as is typical for our conventionalclonal antibodies to TGF-b1 followed by a biotinylated
secondary antibody and an avidin±biotin complex. As specific pathogen±free NOD colony. In contrast, only
30% of transgenic females became diabetic during theshown in Figure 1, islets of transgenic mice stained
strongly for thepresence of TGF-b1 (Figure 1A), whereas 10-month observation period, as determined by BGL
remaining below 250 mg/dl (p 5 0.0075). Although 25%nontransgenic islets did not (Figure 1B).
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2) and are thus referred to as protected ins-TGF-b1
mice.
To further investigate whether TGF-b1 had induced a
state of functional tolerance to islet antigens, pancreata
from newborn nontransgenic NOD mice were grafted
under the left kidney capsule of 7-month-old (protected)
ins-TGF-b1 mice (n 5 8). Two weeks later, histological
analysis of the engrafted pancreata revealed intact islets
that stained strongly for insulin (Figure 1I).
TGF-b1 Itself Cannot Protect against
Diabetogenic T Cells
TGF-b1 has been reported to have the ability to directly
inhibit T cell function in vitro (Kehrl et al., 1986). To
determine whether TGF-b1 could act locally to protect
islets against diabetogenic T cells, pancreata from new-
Figure 2. Cumulative Diabetes Incidence of Female ins-TGF-b1 born ins-TGF-b1 mice and their nontransgenic litter-
Mice and Their Nontransgenic Littermates mates were grafted under the kidney capsule of overtly
BGL weredetermined monthly using GlucometerElite blood glucose diabetic NOD recipients (n 5 8/group). Immunohisto-
test strips. Mice were scored as diabetic after two consecutive
chemical staining showed that within 14 days, graftsmeasurements above 250 mg/dlBGL. There was a significant reduc-
from both NOD mice (data not shown) and ins-TGF-tion (p 5 0.0075) in the incidence of diabetes in ins-TGF-b1 (n 5
b1 mice were destroyed (Figure 1J). Subsequently, to30) compared with their NOD littemates (n 5 21).
confirm the inability of TGF-b1 to regulate diabetogenic
cells within the local pancreatic environment, spleno-
cytes from overtly diabetic NOD mice were transferred
of the transgenic males also became diabetic, the onset into irradiated 8-week-old ins-TGF-b1 (n 5 8) and NOD
was delayed from 16 to 24 weeks of age (data not recipients (n 5 8). Diabetes developed in all recipients
shown). within 4 weeks posttransfer, as evidenced by BGL (Table
Histological analysis of pancreata from nontransgenic 1B) and the destruction of insulin-positive islets (Figures
NOD mice at the onset of diabetes (16 weeks) revealed 1G and 1H).
severe insulitis in most islets (Figure 1C). However, pan-
creata from both 16-week- and 8-month-old ins-TGF-
b1 transgenic mice contained intact islets with only peri- The Islet Antigen-Specific T Cell Response of
ins-TGF-b1 Mice Relies on Distinct APCinsulitis (Figure 1D). These ins-TGF-b1 mice exhibited
extracellular matrix deposition that altered the morphol- GAD is an important islet antigen in IDDM in humans
(Endl et al., 1997), and T cell responsiveness to GADogy of some islets but did not affect the total islet mass.
coincides with the onset of insulitis in NOD mice (Kauf-
man et al., 1993; Tisch et al., 1993). Since TGF-b1 canExpression of TGF-b1 in the Context of Self-Antigen
Induces Funtional Tolerance suppress antigen-specific responses in vitro, we investi-
gated whether pancreatic expression of TGF-b1 influ-Splenocyte transfer experiments were performed to de-
termine whether the degree of protection (70%) in the enced T cell reactivity to this islet antigen. Using en-
riched populations of T cells and mitomycin-C-treatedtransgenic colony correlated with the inability to transfer
disease. Two sets of ins-TGF-b1 mice were used for B cells (n 5 10) and macrophages (n 5 10), we found
that when B cells were used as antigen-presenting cellsthese transfers: 12-week-old mice (these preprotected
mice are too young to determine whether they will de- (APC), T cells from NOD mice proliferated well in re-
sponse to GAD (Figure 3A). However, when macro-velop disease or not) and 8-month-old mice that exhibit
permanent protection (protected). Splenocytes from phages were the APC, T cells from NOD mice did not
proliferate (Figure 3B). In contrast, T cells from ins-ins-TGF-b1 mice and nontransgenic controls were trans-
ferred into NOD±severe combined immunodeficient (scid) TGF-b1 donors responded preferentially to GAD pre-
sented by macrophages (Figure 3B). Proliferation of Trecipients, and BGL were monitored weekly. Each recip-
ient NOD±scid mouse received splenocytes from a sep- cells was consistent following stimulation with GAD re-
gardless of whether macrophages or B cells were self-arate donor. As shown in Table 1A, all NOD±scid mice
(ten of ten) that received cells from 12-week-old NOD derived or exchanged between ins-TGF-b1 and NOD
mice. This outcome reflected a difference between thedonors became diabetic (Figure 1E), whereas only five
of ten of the 10-week-old ins-TGF-b1 mice transferred T cells from ins-TGF-b1 and NOD mice (p , 0.0001),
rather than a difference in the APC populations. In sup-diabetes into NOD±scid recipients (p , 0.001) (Figure
1F). In addition, splenocytes obtained from ins-TGF-b1 port of this, fluorescence-activated cell sorter (FACS)
analyses of both B cells (B2201) and macrophagesmice that had not developed diabetes by 7±8 months
of age were unable to transfer disease into NOD-scid (Mac-11) from splenocytes derived from both ins-TGF-
b1 and NOD mice indicated nodifferences in the expres-recipients (zero of eight, p , 0.0001) (Table 1A). These
mice that do not transfer disease represent the group sion of the costimulatory molecules B7-1, B7-2, and
CD40 between the two groups (data not shown).of transgenic mice that do not develop diabetes (Figure
Immunity
604
Table 1. Incidence of Diabetes after Adoptive Transfer of Splenocytes
Weeks Posttransfer
Donor Mice Recipient Mice 2 3 4 5 6 8 10 11 15
ins-TGF-b1 preprotected
(12-week-old) NOD±scid 0/10 Ð 0/10 Ð 0/10 0/10 3/10 5/10 5/10
ins-TGF-b1 protected
(7±8-month-old) NOD±scid 0/8 Ð 0/8 Ð 0/8 0/8 0/8 0/8 0/8
NOD NOD±scid 0/10 Ð 0/10 Ð 1/10 2/10 8/10 10/10
(12-week-old)
NOD (diabetic) ins-TGF-b1 0/8 1/8 4/8 8/8
(8-week-old)
NOD (diabetic) NOD 0/8 4/8 7/8 8/8
(8-week-old)
The frequency of transfer of IDDM by ins-TGF-b1 mice agrees with the degree of immunoprotection. 107 splenocytes from 12-week-old NOD,
12-week-old preprotected ins-TGF-b1, or 7±8-month-old ins-TGF-b1 mice were transferred (intravenously) into 8-week-old NOD±scid recipients.
Blood glucose levels were monitored at weekly intervals. Transfer of diabetes by diabetogenic splenocytes: 107 splenocytes were obtained
from overtly diabetic female NOD mice and transferred (intravenously) into 8-week-old irradiated ins-TGF-b1 or NOD mice. Blood glucose
levels were monitored at weekly intervals. Ð indicates not done.
TGF-b1 Inhibits APC Function B cells and macrophages from ins-TGF-b1 mice (n 5
10) and NOD mice (n 5 10) with 1 ng/ml exogenousTGF-b1 has a number of inhibitory effects on APC func-
tion; in particular, its ability to inhibit antigen capture TGF-b1 overnight, before washing well and adding to
enriched populations of T cells from both groups, andvia membrane immunoglobulin (mIg) on B cells may be
important because this appears to be the major mecha- then stimulated these cells with GAD protein. As shown
in Figure 3, TGF-b1 decreased the APC ability of B cellsnism for B cell uptake of GAD in NOD mice (Falcone et
al., 1998). In this regard, it is likely that production of (Figure 3C) to a significantly greater extent than macro-
phages (p , 0.0001) (Figure 3D). Inhibition of prolifera-TGF-b1 within the local pancreatic environment affects
APC utilization of GAD and the peripheral development tion by TGF-b1 treatment of APC was not observed
when concanavalin A was used as the stimulus (dataof the GAD-specific T cell repertoire in the ins-TGF-b1
mice. We therefore incubated enriched populations of not shown) but was most clearly shown when NOD T
Figure 3. ins-TGF-b1 and NOD T Cells Rely
on Distinct APC for Presentation of GAD
Protein
T cell and mitomycin-C-treated B cell and
macrophage populations were each enriched
from splenocyte preparations of individual
mice.
(A) T cells from ins-TGF-b1 mice were tested
for proliferation in response to GAD pre-
sented by their own B cells and B cells from
individual NOD mice. Likewise, NOD T cells
were tested for proliferation in response to
GAD presented by their ownB cells and those
from individual ins-TGF-b1 mice. (Back-
ground: 945, 980 cpm.)
(B) The same format was used for experi-
ments using macrophages to present GAD to
ins-TGF-b1 and NOD T cells. (Background:
564, 602 cpm.)
TGF-b1 inhibits APC function in (C) and (D).
(C) B cells from individual ins-TGF-b1 and
NOD mice were incubated overnight with 1
ng/ml of porcine TGF-b1, washed 3 times in
HL-1 medium, and used to present GAD pro-
tein to enriched T cell populations from both
groups.
(D) The same format was used for experi-
ments using TGF-b1-treated macrophages.
Proliferation was determined by the addition
of 1 mCi of [3H]thymidine for the last 18 hr of
a 4 day culture. * indicates mean value is
significantly greater. Data are expressed as
the means 6 SD (n 5 10 mice from each
group) from four separate experiments, each
performed in triplicate.
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Figure 4. T Cells from ins-TGF-b1 and NOD Mice Exhibit Different Profiles of GAD Recognition
Individual ins-TGF-b1 and NOD mice were tested for proliferative responses to GAD and GAD-derived peptides presented by whole splenocytes
(n 5 20 for each group) (A) and T cells (n 5 15 for each group) utilizing B cells (B) or macrophages as APC (C). Splenocytes (2.5 3 105) or
5 3 104 T cells and 5 3 104 APC were cultured in the presence of GAD and the GAD-derived peptides indicated. Proliferation was determined
by the addition of 1 mCi of [3H]thymidine for the last 18 hr of a 4 day culture. Unstimulated proliferation is indicated by the broken line. (*)
indicates mean value is significantly greater. Data are expressed as the means 6 SD of triplicate determinations from seven (splenocytes)
and four (T cells) separate experiments. Polarized Th2 responses in ins-TGF-b1 mice. Splenocytes from ins-TGF-b1 mice release a higher
ratio of IL-4:IFNg than NOD splenocytes in response to GAD and GAD-derived peptides. 2.5 3 105 splenocytes from individual ins-TGF-b1
(n 5 18) and NOD (n 5 18) mice were cultured in the presence of GAD and the GAD-derived peptides indicated. After 48 hr IL-2 (D) and IL-4
(E) release was measured by NK-3 bioassay, and IFNg (F) release was measured by ELISA. (*) indicates mean value is significantly greater.
Data are expressed as the means 6 SD of triplicate determinations from six separate experiments.
cells, which preferentially utilize B cells for presenta- mice; therefore, these data were combined. This group
of ins-TGF-b1 mice proliferated extremely vigorously totion of GAD, were used as the responder population
(Figure 3C). peptide 36, which induced a low level of proliferation
in NOD splenocytes (Figure 4). Splenocytes from NOD
littermates showed proliferative responses to the GADIslet Expression of TGF-b1 Results in a Distinct
Peripherally Expanded or Influenced peptides 6, 15, and 35, the strongest being to peptides
6 and 15 (Figure 4A). In addition, splenocytes from 35%GAD-Specific T Cell Repertoire
To assess this response to GAD in greater detail, we of the 10-week-old ins-TGF-b1 mice exhibited prolifera-
tive responses that mirrored those from NOD spleno-used synthetic peptides derived from the GAD protein
sequence (Atkinson et al., 1994). These peptides contain cytes (data not shown). We predict that these represent
those transgenic mice that would not be protected fromT cell epitopes, which have been shown to be critical
for immunopathogenesis in the NOD mouse, and they diabetes.
Because T cells derived from NOD mice and ins-were selected based on previously published reports
on their recognition by NOD T cells via recall responses. TGF-b1 mice exhibited different APC preferences for
utilization of whole GAD protein, we again used enrichedGAD peptides 6 and 15 have been suggested to contain
immunodominant T cell epitopes; peptide 35 induces populations of T cells and mitomycin-C-treated B cells
and macrophages to test responses to GAD-derivedintermediate T cell responses and peptide 36 contains
only minor epitope(s) (Kaufman et al., 1993). Therefore, peptides. We assumed that these peptides (20-mer)
would not undergo extensive processing, and thereforewe would predict that T cell responses to these peptides
would be equal in the NOD mouse, and we were inter- responses to these peptides would indicate whether
this difference in APC preference for presentation ofested in whether responses to these GAD peptides
would differ in our ins-TGF-b1 mice. GAD protein reflected a difference in APC function, such
as costimulatory requirements of T cells from ins-TGF-Whole splenocytes from 7- or 8-month-old protected
and 10-week-old ins-TGF-b1 mice (n 5 20) and their b1 and NOD mice, for example. As shown in Figure 4,
when macrophages were used to present GAD peptides,NOD littermate controls (n 5 20) were stimulated in vitro
with whole GAD or GAD-derived peptides (peptides 6, T cells from ins-TGF-b1 mice (n 5 15) proliferated better
to peptide 36 than did T cells from NOD mice (n 5 15)15, 35, and 36). Splenocytes from the transgenic mice
proliferated less well in response to GAD than spleno- (Figure 4B). However, when macrophages were used
to present peptides 6 and 15, ins-TGF-b1 T cells re-cytes from NOD mice (Figure 4). The proliferation profile
of splenocytes from 65% of 8- to 10-week-old prepro- sponded poorly, with responses to peptide 35 being
intermediate. In contrast, NOD T cells responded ex-tected transgenic mice exactly matched (p 5 0.95) that
from the long-term protected (8-month-old) transgenic tremely well to peptides 6 and 15 and much less well
Immunity
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Figure 5. Histological Analyses of Pancreata
from NOD-scid Recipients of ins-TGF-b1 and
NOD Splenocytes
Splenocytes from protected ins-TGF-b1 do-
nors (7- to 8-month-old) do not initiate de-
struction of NOD±scid islets (A) unless the
recipient is treated with anti-IL-4 (B) stained
for insulin. Splenocytes from NOD mice (14-
week-old) do not inhibit the transfer of diabetes
by splenocytes from overtly diabetic donors;
(C) shows pancreas from NOD±scid recipient
of a 1:5 ratio of diabetic:NOD splenocytes
stained for insulin. Conversely, NOD±scid re-
cipients of 1:5 (D) and 1:10 (E) ratios of dia-
betic cells:ins-TGF-b1 splenocytes are pro-
tected from disease, but ratios of 1:1 and 1:2
(F) are not inhibitory. (A)±(D) are 2003 and (E)
and (F) are 1003 magnification.
to peptide 36. Again, responses to peptide 35 were inter- determine whether islet expression of TGF-b1 could in-
fluence Th subset development in our transgenic mice,mediate.
The pattern of proliferative responses of both ins- we measured GAD-specific Th1 (IFNg), Th2 (IL-4), and
TGF-b1 cytokine release in the ins-TGF-b1 mice (n 5TGF-b1 and NOD T cells when B cells were used to
present peptides was similar to that described for mac- 18) and compared these responses to those from NOD
mice (n 5 18). Whole splenocytes from ins-TGF-b1 androphages (Figure 4C). Taken together, these findings
showed that the GAD-specific T cell repertoires in ins- NOD mice were stimulated with GAD protein or GAD-
derived peptides. Supernatants from these culturesTGF-b1 mice and NOD mice were distinct and re-
sponded equally well or poorly to the same GAD-derived were tested for the presence of IFNg and TGF-b1 and for
IL-2 and IL-4 by enzyme-linked immunosorbent assaypeptides whether splenocytes (Figure 4A), B cells (Fig-
ure 4B), or macrophages (Figure 4C) were used as the (ELISA) and the NK-3 bioassay, respectively. After 48 hr
of stimulation with GAD protein, supernatants from NODAPC. This suggested that the differences in responses
to whole GAD protein by T cells from ins-TGF-b1 and mice contained levels of IL-2 that mirrored the degree
of proliferation (Figure 4D). In the protected ins-TGF-b1NOD mice were not solely due to different requirements
for an APC function, such as costimulation, provided by mice, the levels of IL-4 produced in response to GAD
were relatively high (Figure 4E), with less IL-2 (Figure 4D)macrophages and B cells.
and no IFNg (Figure 4F) detected. The ratios of IL-4:IFNg
release from splenocytes in response to GAD were 90-Islet Expression of TGF-b1 Results in the Polarization
of GAD-Specific Responses toward fold greater in ins-TGF-b1 mice (5.2) than in NOD mice
(0.06, p , 0.0001). The release of TGF-b1 was not de-a Th2 Phenotype
TGF-b1 can influence Th effector cell development, both tected in response to GAD from either NOD or ins-TGF-
b1 splenocyte cultures (data not shown).directly, upon the survival and expansion of Th2 ef-
fectors (Zhang et al., 1995), and indirectly, via inhibition When GAD peptides were used to stimulate spleno-
cytes from ins-TGF-b1 or NOD mice, IL-4 was producedof APC function and the effective lowering of antigen
dose (Constant et al., 1995; Hancock et al., 1995). To to a similar extent (Figure 4E). GAD peptides 6 and 15
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induced the release of IL-4 from splenocytes of pro- IL-4 Blockade of ins-TGF-b1 Splenocytes Unleashes
tected ins-TGF-b1 mice, but no IFNg was detected (Fig- Potentially Diabetogenic Th1 Cells
ure 4F). Splenocytes from these mice did release some Because of thecross-regulatory effects of IL-4 and IFNg,
IFNg on stimulation with peptides 35 and 36. Conversely, we investigated whether the onset of diabetes following
NOD splenocytes proliferated and released IFNg in re- IL-4 blockade coincided with an islet antigen-specific
sponse to all GAD peptides tested. For peptides 6 and increase in IFNg production in ins-TGF-b1 mice. Spleno-
15, the ratios of IL-4:IFNg released from ins-TGF-b1 cytes from NOD±scid recipients of splenocytes from
cells were significantly higher (GAD peptide 6, 1.7; GAD protected ins-TGF-b1 mice, with and without anti-IL-4
peptide 15, 1.1) than the same ratios of release from administration, were tested for proliferation and cyto-
NOD cells (peptide 6, 0.027; peptide 15, 0.05, p , 0.001) kine release in response to GAD protein and peptides.
(Figure 4). These results show a lack of, or decrease in, NOD±scid recipients of splenocytes from ins-TGF-b1
IFNg production in response to GAD peptides 6 and 15 mice not treated with anti-IL-4 had low proliferative indi-
that is consistent with poor proliferative responses to ces, little IL-2 production, and negligible IFNg produc-
these peptides in the ins-TGF-b1 mice. Again, TGF-b1 tion in response to GAD and GAD peptides 6 and 15.
was not detected in supernatants from either NOD However, GAD peptide 36 induced strong proliferation
or ins-TGF-b1 splenocytes cultured with GAD-derived and IL-2 and IFNg release (Figure 6). After anti-IL-4 ad-
peptides (data not shown). These findings suggest that ministration, the proliferative indices and cytokine pro-
the source of IL-4 in response to whole GAD protein files both changed. Splenocytes recovered from NOD±
in the ins-TGF-b1 mice was to a GAD-derived peptide scid recipients of ins-TGF-b1 cells underwent increases
(epitope) not yet tested. Despite the markedly greater in proliferation in response to GAD peptides 15 and 35,
proliferative response to peptide 36 by transgenic cells but proliferation (Figure 6A) and IL-2 production (Figure
versus NOD, the IFNg and IL-4 production were the 6B) in response to peptide 36 was slightly decreased.
same in these two groups. IL-4 release was low or not detectable for responses to
When B cells or macrophages were used to present all peptides (Figure 6C), but IFNg release was greatly
GAD to T cells from ins-TGF-b1 (n 5 15) or NOD mice increased after stimulation with GAD protein and pep-
(n 5 15), the resulting cytokine profiles differed. That is, tide 15 (Figure 6D). Following IL-4 blockade, the ratios
NOD T cells released 600-fold higher ratios of IFNg:IL-4
of IFNg:IL-4 increased from 0.03 to 3.8 for GAD (p ,
(23.9) than T cells from ins-TGF-b1 mice (0.04, p ,
0.0001), 0.1 to 22.2 for peptide 15 (p , 0.0001), and 0.08
0.0001). In response to peptides 6 and 15, IFNg was
to 0.8 for peptide 6 (p , 0.0001) (Figure 6). These findings
produced in significant amounts only by NOD T cells
confirmed that IL-4 plays a direct and continuing role
whether the APC were B cells or macrophages. While
in the down-regulation of IFNg production in the ins-
macrophages induced IL-2 secretion, B cells induced a
TGF-b1 mice.greater release of IFNg and IL-4 or both fromboth groups
of T cells, consistent with stimulation of a more mature
(effector) T cell populaton (data not shown). Splenocytes from ins-TGF-b1 Mice Inhibit Islet
Destruction by Diabetogenic T Cells
TGF-b1 Protects via Polarization of the Anti-Islet
Since the polarization of T cell responses to an IL-4-Response toward an IL-4-Producing
producing Th2 phenotype is associated with the preven-Th2 Phenotype
tion of diabetes, we tested the potential inhibitory effectsThe polarized Th2 response to GAD antigen indicated
of ins-TGF-b1 splenocytes on diabetogenic cells. Sple-the probable importance of IL-4 in the immunoprotec-
nocytes from protected transgenic (n 5 6) and 14-week-tion of our ins-TGF-b1 mice; therefore, we used the
old nontransgenic (n 5 4) mice were mixed with sple-neutralizing monoclonal antibody (mAb) 11B11 in an at-
nocytes from diabetic NOD mice at a range of ratiostempt to inhibit the effects of IL-4. NOD±scid recipients
(diabetic splenocytes: ins-TGF-b1 or NOD splenocytes,of 107 splenocytes from protected (8-month-old) ins-
1:1, 1:2, 1:5, 1:10), and these mixtures were transferredTGF-b1 mice (n 5 8) that did not transfer disease (Table
(intravenously) into NOD±scid recipients. BGL, moni-1A), 14-week-old NOD mice (n 5 8), and protected ins-
tored at weekly intervals, showed that splenocytes fromTGF-b1 mice themselves (n 5 4) were injected (intrave-
NOD mice only slightly delayed the onset of diseasenously) with this anti-IL-4 antibody (1 mg total) every
induced by diabetic cells (Table 2 and Figure 5C). How-other day for 1 week. BGL monitored weekly and immu-
ever, splenocytes from ins-TGF-b1 mice delayed thenohistochemistry showed that recipients of splenocytes
ability of diabetic splenocytes to transfer disease at ra-from ins-TGF-b1 mice alone and those given ins-TGF-
tios 1:5 (Figure 5D) and 1:10 (Figure 5E) and inhibitedb1 splenocytes and isotype control (YCATE) antibody
disease expression (by 20 weeks after transfer) in fourdid not develop diabetes (Table 2 and Figure 5A).
of six donor mice (p , 0.001).However, those that received the same splenocytes in
Unexpectedly and outside of the scope of the presentconjunction with anti-IL-4 developed diabetes within 8
study, some of the recipients of ins-TGF-b1 and diabeticweeks of transfer (p , 0.0001) (Table 2 and Figure 5B).
splenocyte mixtures developed a wasting disorder, los-NOD±scid control recipients of NOD splenocytes devel-
ing 15%±20% of their total body weight during theoped diabetes by 5 weeks of transfer whether or not they
course of the experiment. This disorder only occurredwere treated with anti-IL-4 or control antibody (Table 2).
in those mice that had received 1:1 and 1:2 ratios (FigureUnlike transferred cells, ins-TGF-b1 mice that received
5F) of diabetogenic NOD, ins-TGF-b1 cells, and prelimi-the same regimen of anti-IL-4 treatment, or control anti-
nary data indicate severe inflammation of the intestinalbody, remained free of diabetes by 8 weeks after treat-
ment (data not shown). mucosa was the cause. Five mice from this group had
Immunity
608
Table 2. Incidence of diabetes after adoptive transfer of splenocytes
Weeks Posttransfer
Cell Source Mixing Ratio Antibody 2 3 4 5 6 7 8 10 12 14 16 18 20
ins-TGF-b1 Nil 0/8 0/8 0/8 0/8 0/8 0/8 0/8
ins-TGF-b1 Anti-IL-4 0/8 0/8 0/8 0/8 2/8 4/8 8/8
ins-TGF-b1 YCATE 0/8 0/8 0/8 0/8 0/8 0/8 0/8
NOD Nil 0/8 0/8 3/8 7/8 8/8
NOD Anti-IL-4 0/8 0/8 3/8 7/8 8/8
NOD YCATE 0/8 0/8 2/8 8/8
Diabetic NOD 1:0 Ð Ð Ð Ð 4/4
Diabetic NOD:
Ins-TGF-b1 1:1 Ð Ð Ð Ð 0/6 Ð 1/6 5/6 6/6
1:2 Ð Ð Ð Ð 0/6 Ð 1/6 1/6 3/6 6/6
1:5 Ð Ð Ð Ð 0/6 Ð 0/6 0/6 1/6 1/6 2/6 2/6 2/6
1:10 Ð Ð Ð Ð 0/6 Ð 0/6 0/6 0/6 0/6 0/6 2/6 2/6
Diabetic NOD:
NOD 1:1 Ð Ð Ð Ð 0/5 Ð 5/5
1:2 Ð Ð Ð Ð 0/5 Ð 5/5
1:5 Ð Ð Ð Ð 1/5 Ð 4/5 5/5
1:10 Ð Ð Ð Ð 1/5 Ð 5/5
developed diabetes, undetected by BGL of .250 mg/dL, did not directly affect fully established diabetogenic T
cells; instead, the expression of islet antigen in the con-as evidenced by massive destruction of insulin-staining
islets by immunohistochemistry (Figure 5F), and were text of TGF-b1 yielded a nondestructive response to
islet antigens by preventing the development of an IFNg-included in Table 2 as diabetic mice.
producing T cell phenotype.
Discussion
Differences in APC Preference for T Cell
Recognition of Islet AntigenTGF-b1 induced transgenically in pancreatic islets pre-
vented the development of IDDM in NOD mice, signifi- Our results revealed a difference in preference for APC
in ins-TGF-b1 versus NOD mice. The proliferative re-cantly reducing its incidence from 75% to 30% of females.
TGF-b1 also prevented insulitis butnot periinsulitis, sug- sponses of purifed ins-TGF-b1 T cells to GAD protein
were greatest when macrophages were used as APC.gesting that islet-specific T cells homed to the pancreas
but failed to elicit immune destruction. Grafting and In contrast, NOD T cells proliferated well when B cells
were used to present GAD but failed to proliferate at alladoptive transfer experiments showed that TGF-b1 itself
Figure 6. anti-IL-4 mAb Treatment of ins-
TGF-b1 Splenocytes Unleashes IFNg-Pro-
ducing Th1 Cells
Splenocytes from ins-TGF-b1 mice (n 5 8)
recovered from NOD±scid recipients each
with and without anti-IL-4 treatment were
tested for proliferation and cytokine release
in response to GAD and the GAD-derived
peptides indicated. (A) Proliferation was de-
termined by the addition of 1 mCi of [3H]thymi-
dine for the last 18 hr of a 4-day culture. Un-
stimulated proliferation is indicated by the
broken line. IL-2 (B) and IL-4 (C) release was
measured by NK-3 bioassay, and IFNg (D)
release was measured by ELISA. (*) indicates
mean value is significantly greater. Data are
expressed as the means 6 SD of triplicate
determinations.
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in the presence of macrophages. Since T cells from detailed analyses will need to be performed to investi-
gate the GAD antigen-specific B cell repertoires in theseins-TGF-b1 or NOD mice proliferated consistently when
stimulated with GAD, regardless of whether macrophages mice.
or B cells came from a transgenic or nontransgenic
source, the cause was a difference in the T cell popula- Shift in Immunodominance of GAD-Epitopes
tions and not a difference in the APC populations. It is via Localized Expression of TGF-b1
unlikely that the differences inpreference for APCcan be Our studies clearly showed that TGF-b1 more markedly
explainedby differences in T cell affinity orcostimulatory inhibited the APC ability of B cells than macrophages
requirements, because both macrophages and B cells in vitro. In the ins-TGF-b1 mice, the progession from
were able to present GAD peptides to T cells from each dendritic cell/macrophage to B cell utilization of GAD
group. A possible explanation is that our results reflect antigen may not develop, due to silencing of B cell anti-
differences in the effector state or maturity of GAD- gen-presenting capacity by TGF-b1. This expansion of
specific T cells in the two groups or, alternatively, differ- the spontaneous islet antigen-specific T cell response
ences in the T cell repertoires that have developed dur- in vivo may be reflected in the distinct GAD-specific in
ing the course of macrophage or B cell processing and vitro recall responses observed between NOD and ins-
presentation of islet antigen. TGF-b1 mice. The peptides producing the strongestpro-
liferation of ins-TGF-b1 T cells were located toward the
carboxy terminus of the GAD protein (e.g., GAD-derivedExpansion of T Cells Reactive to Distinct
peptide 36), whereas those peptides located toward theGAD-Derived Peptides via Different APC
N terminus (e.g., GAD-derived peptides 6 and 15) of theAlthough islet expression of TGF-b1 did not down-regu-
GAD protein sequence produced the greatest prolifera-late APC function to the endpoint of T cell anergy, there
tion of NOD T cells. In this regard, a similar trend of de-are a number of ways that TGF-b1 might impact on APC
terminant diversification has been reported in a model offunction. The ability of TGF-b1 to prevent B cell antigen
autoimmune arthritis (Moudgil et al., 1997), but whethercapture via mIg (Kehrl et al., 1991) could be critical in
this trend is related to the pathogenicity of T cell clonesthe peripheral shaping of a nonpathogenic T cell reper-
in IDDM remains unclear.toire in the ins-TGF-b1 mice. The down-regulatory effect
Of the peptides we have tested thus far, the dominanton B cells in the ins-TGF-b1 mice may aid protection
T cell epitope(s) in the protected transgenic mice werefrom IDDM because B cells are critical for efficient
clearly contained within GAD peptide 36. T cells specificexpansion of antigen-specific T cell responses (Ron and
for peptide 36 in the transgenic mice were clearly moreSprent, 1987), and because B cells can differentially
Th1-like than Th2-like, but T cell populations containingprocess antigen, revealing cryptic epitopes (Lanzavec-
cells of this specificity were not diabetogenic. Further-chia, 1987, 1995; Simitsek et al., 1995). This has pre-
more, the strong proliferative response to peptide 36 inviously been suggested to be a means by which autore-
protected transgenic mice was not observed in NODactive T cells can expand in the periphery (Mougdil and
mice. This heightened response was therefore likely toSercarz, 1993; Mamula et al., 1994; Roth et al., 1997).
result from processing and presentation of GAD byPreferential processing and presentation of GAD by
APC(s) that have seen antigen in a TGF-b1 environment.macrophages in ins-TGF-b1 mice and by B cells in NOD
There are a number of possible explanations for themice may lead to differences in the peripherally ex-
heightened response to peptide 36. T cells reactive topanded, or peripherally influenced, GAD-specific T cell
a minor or subdominant epitope such as peptide 36 mayrepertoires (Schneider and Sercarz, 1997). B cells take
expand as T cells reactive to the major GAD epitopesup GAD antigen via surface immunoglobulin in the NOD
are inhibited or deleted from the repertoire and competi-mouse (Falcone et al., 1998) and have been shown to
tion at the APC site diminishes. Alternatively, reactivitytake up antigen±antibody complexes via mIg, which af-
to peptide 36 may precede reactivity to other epitopesfects the processing of peptide antigen and, ultimately,
in NOD mice but decrease as the antigen-presentingwhich epitope is presented (Lanzavecchia, 1987; Simit-
role of B cells grows. As a chemoattractant (Wahl et al.,sek et al., 1995). In the NOD mouse, the T cell epitopes
1987), TGF-b1 might draw monocytes into the islets tothat become dominant may be defined by the ongoing
preferentially process and present GAD. In this regard,resonance between the B cell and T cell repertoires.
the dominance of peptide 36 would be maintained inOnce autoimmunity is established, the more mature ex-
the ins-TGF-b1 mice, but it may be presented by macro-panded T cell repertoire in the NOD mouse, which has
phages only early in the course of autoimmunity in thebeen shaped by B cell processing and presentation of
NOD mouse.islet antigen, may no longer be specific to GAD epitopes
presented by macrophages, or these T cells may exist
at a very low frequency. Moreover, it is possible that Polarization of GAD-Specific Responses to Th2
T cell responses to GAD protein in the transgenic micethe T cells responsive to GAD epitopes that are more
effectively deleted in the NOD mouse are those that were deviated away from IFNg production and toward
an IL-4-producing Th2 phenotype, with no detectableare processed and presented by macrophages. In this
regard, we might expect NOD mice to contain an ex- TGF-b1 production. This heightened IL-4 release was,
presumably, to a GAD-derived epitope(s) not yet tested.panded repertoire of GAD-reactive B cells, and whilst
our findings indicated a slightly increased NOD T cell The release of cytokines from ins-TGF-b1 T cells empha-
sized the importance of the relative amounts of IL-4 andproliferative response when we used B cells from NOD
mice as the APC, this was not significant. Further, more IFNg in determining polarization of islet antigen-specific
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effector cell populations to Th2. The absolute amount Th1 cells from gaining the antigen and costimulatory
requirements necessary for their survival or expansionof IL-4 released by ins-TGF-b1 splenocytes from in vitro
recall of spontaneous in vivo responses did not appear (Webb and Feldmann, 1995; Zhang et al., 1997). Recent
evidence that TGF-b1 prevents apoptotic death of Th2to be great compared with the release of IL-4 from in
vitro polarized T cell clones, for example. However, this effectors (Zhang et al., 1995) suggests that the TGF-b1
environment in the pancreas may promote the expan-amount of IL-4 was clearly adequate to down-regulate
the development of an IFNg-producing Th1 response to sion of isletantigen-specific Th2 cells, further preventing
diabetogenic Th1 cells from eliciting destruction.islet antigens, and in another study, the release of 1 pg
of IL-4 per islet over 48 hr was found to be adequate to The observation that TGF-b1 did not prevent diabetes
in all of the transgenic mice may reflect the balanceprotect NOD mice from IDDM for their entire lifetime
(Mueller et al., 1996). The use of ratios of Th2:Th1 cyto- between proinflammatory, pathogenic Th1 cells and reg-
ulatory Th2 cells. The state of functional tolerance tokines released in response to GAD is a useful means of
determining polarization of Th responses to an antigen islet antigens driven by IL-4 would not necessarily be
dominant in all mice, since it would depend upon cor-(Hsieh et al., 1993). By this measure, ins-TGF-b1 T cells
produced a 90-fold greater ratio of IL-4:IFNg release in rectly timed interactions between naive T cells, or Th1
cells, and Th2 cells at the site of antigen presentation.response to GAD than NOD T cells (p , 0.0001).
The mechanism that drives the polarization of islet The production of Th1 cytokines in response to autoanti-
gen appears to be important in autoimmune diseaseantigen-specific T cell responses in these mice is not
yet clear, but our findings suggest that islet expression pathogenesis in the NOD mouse. In this context, the
polarization of islet antigen-specific T cell responses toof TGF-b1 resulted in diminished production of IFNg
responses, which was sufficient to support Th2 subset Th2 has a correcting effect on the NOD genetic back-
ground and retards the progression of autoimmunity.development. Possibly, TGF-b1 production leads to Th2
differentiation via down-regulation of APC function lead- That is, the TGF-b1 milieu at the site of islet antigen
normalizes the NOD T cell repertoire so that the regula-ing to low-avidity interactions, or limited antigen dose,
and preferential development of T cells of the Th2 phe- tory capacity of IL-4 holds in check the expression of
an autoaggressive phenotype.notype (Hosken et al., 1995). Previously, in a model of
anterior chamber autoimmune disease (ACAID), macro- In summary, TGF-b1 shifts APC preference for the
presentation of islet antigen from B cells to macro-phages produced TGFb2 in an autocrine fashion, which
deviated immune responses toward a noninflammatory phages, resulting in distinct peripherally expanded T
cell repertoires. The NOD islet antigen-specific T cellTh2 phenotype (Takeuchi et al., 1997). Similarly, in our
transgenic mice, macrophages might carry the ability to repertoire, shaped by the B cell repertoire, is diabeto-
produce TGF-b1 from the islets into the draining lymph genic. However, the less developed T cell repertoire of
nodes of the pancreas and thereby diminish APC±T cell protected ins-TGF-b1 mice does not progress beyond
interactions, lessening the availability of antigen and macrophage processing and presentation of islet anti-
favoring IL-4-producing Th2 cells. gen. Similar to a mucosal environment, TGF-b1 expres-
sion in the pancreatic islets inhibits the production of
Active Tolerance via IL-4 Production islet antigen-specific Th1 cells, and the diminished IFNg
The inhibition of diabetogenic T cell responses by sple- production is sufficient to support Th2 development.
nocytes from protected ins-TGF-b1 mice suggests that The driving force behind the observed polarization to-
IL-4 imposes an active state of tolerance. When this ward Th2 and away from Th1 may be due to the less-
active regulation in ins-TGF-b1 splenocytes was over- ening of antigen dose delivered to T cells by TGF-b1-
whelmed by equivalent ratios of diabetogenic spleno- induced inhibition of islet antigen capture by B cells.
cytes, autoimmune-type inflammation was no longer Once Th2 polarization is established in the transgenic
confined to the pancreas but was also observed in the mice, IL-4 actively suppresses the expansion of poten-
intestinal mucosa (wasting disease). The development tially diabetogenic Th1 cells, such as those specific to
of diabetes after anti-IL-4 treatment indicates that po- GAD-derived peptide 15, preventing IDDM.
tentially diabetogenic (Th1) cells do exist in these mice
but arecontained via the cross-regulatory effects of IL-4.
T cells from NOD mice produced significant amounts of Experimental Procedures
IFNg in response to GAD-derived peptides 6 and 15,
Generation of Transgenic Micewhereas the reduced IFNg production in response to
The gene encoding porcine TGF-b1 was microinjected into fertilizedGAD in the transgenic mice was highlighted by the com-
NOD zygotes as described previously (Lee et al., 1995). The pres-
plete lack of Th1 cells specific to GAD-derived peptides ence of the transgene was confirmed by polymerase chain reaction
6 and 15. typing of tail DNA. BGL were determined using Glucofilm blood
Following anti-IL-4 treatment, T cell responses to GAD glucose strips (Miles Diagnostic). All mice were housed together
from ins-TGF-b1 mice became more aggressive, with under specific pathogen-free housing conditions at the Scripps ro-
dent colony.increased IL-2 production and IFNg:IL-4 ratios. Particu-
larly striking was the emergence of potentially diabeto-
genic IFNg-producing Th1 cells specific to peptide 15.
mAbs for In Vivo Inhibition
The exact mechanism by which IL-4 actively suppresses The hybridoma generated by Ohara and Paul (1985) secreting the
the expression of IDDM in ins-TGF-b1 mice remains murine IL-4-specific mAb, 11B11, and the hybridoma generated by
unknown, but islet antigen-specific Th2 cells may oper- Cobbold and Metcalfe (1994) secreting the isotype control antibody
(rat IgG2a specific for canine CD8), YCATE, were homegrown.ate in the periphery or home to the islets to prevent
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GAD and GAD-Derived Peptides T Cell Proliferation to GAD and Peptide Antigens
For proliferation assays using enriched cell populations, 5 3 104GAD was expressed and purified as previously described (Kaufman
et al., 1993). Synthetic GAD65 peptides, kindly supplied by Dan Kauf- APC were added to 5 3 104 T cells per well of a flat-bottomed 96-
well culture tray. Enriched populations of macrophages and B cellsman (University of California, Los Angeles), are based on the murine
GAD65 protein sequence and the previously published 20-mer syn- were treated with mitomycin-C (Sigma Chemical) at 50 mg/ml for 40
min and then washed thoroughly before incorporation into prolifera-thetic GAD peptides designed with 5 amino acid overlaps from the
human GAD65 protein sequence (Atkinson, 1994). Their numbering tion assays. Whole splenocytes were used at 5 3 105 cells/well of
a culture tray. Whole splenocytes or T cells plus APC were incubated(6, 15, 35, 36) is directionally based on the GAD protein sequence,
N to C terminus. GAD-derived peptide 6, residues 78±97 (KPC in 0.2 ml of culture medium (HL-1 media [BioWhittaker] and 5 3
1025 M 2-mercaptoethanol) in the presence of 10 mg/ml GAD andNCPKGDVNYAFLHATDL), GAD-derived peptide 15, residues 217±
236 (EYVTLKKMREIIGWPGGSGD), GAD-derived peptide 35, resi- 10 mM GAD-derived peptides. For TGF-b1 treatment of enriched
APC populations, 1 ng/ml porcine TGF-b1 (R & D Systems) wasdues 524±543 (SRLSKVAPVIKAMMEYGTT), and GAD-derived pep-
tide 36, residues 539±558 (EYGTTMVSYQPLGDKVNFFR). added to macrophages or B cells and incubated overnight at 378C;
the cells were then sequentially washed in HL-1 media (3 times) to
remove any exogenous TGF-b1, and the APC were then incorpo-
Immunohistochemical Staining rated into proliferation assays using enriched T cell populations
Paraffin-embedded pancreata and/or kidneys containing graft tis- and 10 mg/ml GAD protein or concanavalin-A (Sigma). The optimal
sue were stained with an immunoperoxidase method using poly- concentrations of cells and GAD protein or peptide used were each
clonal antibodies to porcine insulin (DAKO), synthetic glucagon determined from titration curves. Proliferation was assessed by ad-
(Chemicon), human somatostatin (DAKO), and polyclonal antibodies dition of 1 mCi [3H]tritiated thymidine for the last 18 hr of a 4-day
to porcine TGF-b1 (Wyss-Coray et al., 1997), followed by a biotinyl- assay.
ated secondary antibody and an avidin-biotin complex (Vector).
Cytokine Release in Response to GAD Stimulation
After 48 hr, supernatants from proliferation assays were collectedGrafting of Pancreata
and analyzed for the presence of IFNg, IL-2, and IL-4 using ELISAFor grafting into ins-TGF-b1 or NOD females, pancreata were re-
and bioassay, respectively. IFNg levels were determined usingmoved from newborn ins-TGF-b1 mice and their nontransgenic
homegrown mAb R4±6A2 as the capture antibody and biotinylatedlittermates and grafted under the left kidney capsule of either
polyclonal anti-IFNg (R & D Systems). The concentration of IFNg8-month-old female ins-TGF-b1 transgenic mice or diabetic female
was interpolated from a standard curve using recombinant murineNOD mice. All grafts were removed 2 weeks after surgery and the
IFNg (PharMingen). The standard curve was linear in the range ofgrafts examined histologically.
10±1100 pg/ml. TGF-b1 was also measured by ELISA; polyclonal
anti-TGF-b1 and monoclonal (capture) anti-TGF-b1 were purchased
from R & D Systems. The concentration of TGF-b1 was interpolatedSplenocyte Transfer
from a standard curve using porcine TGF-b1 (R & D Systems) to aDonor cell suspensions were prepared from spleens of transgenic
limit of detection of 150 pg/ml. The detection levels of the IFNgor nontransgenic mice. Red cells were depleted by hypotonic lysis,
and TGF-b1 ELISAs were enhanced with the use of extravidin andand the remaining cells were washed and resuspended at 5 3 107
biotinylated antiavidin (Sigma), and color development was stoppedcells/ml in sterile phosphate-buffered saline. The 8-week-old NOD±
by the addition of 25% H2SO4. IL-4 and IL-2 were measured by thescid females were injected intravenously with 200 ml of the donor
NK-3 bioassay as described previously (Swain et al., 1981; Bradleysplenocyte suspension. BGL were determined weekly starting at 2
et al., 1991). Antibodies for the NK assay for blocking IL-2, home-weeks after transfer.
grown 7D4 11P, kindly supplied by Linda Bradley (Department of
Immunology, Scripps Research Institute), was used at 1:2000, and
combined with JES6 (PharMingen) at 1 mg/ml. For blocking IL-4,Cell Populations for Proliferation and Cytokine Analysis
homegrown 11B11 was used at 1 mg/ml. NK-3 cells were diluted toEnriched cellular fractions wereprepared from individual ins-TGF-b1
1 3 105 cells per well of a 96-well flat-bottomed culture tray, andor NOD females. Splenocytes were obtained by mincing cells
proliferation was determined by the addition of 1 mCi [3H]tritiatedthrough a wire mesh, and red cells were depleted by hypotonic lysis.
thymidine for the last 18 hr of a 2-day culture. The concentrationsT cells, B cells, and macrophages were purified from splenocytes by
of IL-4 and IL-2 were interpolated from a standard curve usingnegative depletion over MACS (magnetic cell sorting) columns (type
recombinant murine IL-4 and IL-2 (R & D Systems). For IL-4 andB2). MACS microbeads were coated with antimouse antibodies ac-
IL-2 the standard curves were linear in the range of 6±1000 pg/ml.cording to the manufacturer's instructions (Miltenyi Biotec) and pu-
rity assessed by FACS analysis. Cells were purified from nonadher-
ent splenocytes (2 hr adherence on a petri dish at 378C/5% CO2) by Statistical Analyses
depleting spleen cell suspensions with MACS microbeads conju- Statistical analyses were performed using the Student's t test.
gated with antimouse CD451 (rat antimouse IgG2a B220 mi-
crobeads) and CD3 (145±2C11) antibodies, or anti-CD11b biotinyl- Acknowledgments
ated Mac-1 antibody (PharMingen) and streptavidin microbeads.
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